Similar effectiveness of R‐CHOP‐14 and ‐21 in diffuse large B‐cell lymphoma—data from the prospective German Tumour Registry Lymphatic Neoplasms

Abstract

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. AbstractObjectives: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is the standard therapy for patients with previously untreated diffuse large B-cell lymphomas (DLBCL). Dose-dense two-weekly 'R-CHOP-14' was not superior over three-weekly 'R-CHOP-21' in randomised clinical trials (RCTs). We present realworld data on effectiveness of R-CHOP-14 and R-CHOP-21 in patients with DLBCL treated in German routine practice. Methods: We identified 582 patients with DLBCL treated with R-CHOP-14 or R-CHOP-21 in 92 sites from the prospective clinical cohort study Tumour Registry Lymphatic Neoplasms. Patients' schedules were classified by (a) length of the initial first cycle and (b) length of cycles 1-4.Results: About 55% of patients received R-CHOP-21, 45% R-CHOP-14, in median 6 cycles. 51% and 55% of patients, respectively, were able to continue their initial R-CHOP-14 and R-CHOP-21 schedule. While most characteristics between the patient cohorts were similar, patients receiving R-CHOP-21 presented slightly more often with tumour stage I and lower IPI risk. 3-year overall survival of patients with R-CHOP-14 and R-CHOP-21 did not differ: 84% vs 84% (first cycle), 87% vs 89% (cycles 1-4). Conclusions:Patients with DLBCL in Germany are slightly more likely to receive R-CHOP-21 than R-CHOP-14. Both schedules are similarly effective in routine practice confirming the results from RCTs. K E Y W O R D Scohort studies, cyclophosphamide, doxorubicin, diffuse large B-cell lymphoma, outpatients, prednisone, prognosis, registries, rituximab, vincristine | 461 KNAUF et Al.

Rare lymphomas in routine practice—Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms

“…Patients were followed for up to 5 years from enrolment or until death, loss to follow‐up or withdrawal of consent. Further details on the methodology of the TLN have been previously described elsewhere 28‐31 …”

“…In this article, we present data on 139 patients with WM who all underwent systemic treatment. Data were collected within the prospective clinical cohort study TLN (Tumour Registry Lymphatic Neoplasms) which had recruited patients with indolent NHL [28][29][30] or aggressive NHL 31…”

“…In this article, we present data on 139 patients with WM who all underwent systemic treatment. Data were collected within the prospective clinical cohort study TLN (Tumour Registry Lymphatic Neoplasms) which had recruited patients with indolent NHL 28‐30 or aggressive NHL 31 treated by office‐ and hospital‐based haematologists in Germany. We show the choice of first‐line treatment (2009‐2014) and second‐line treatment (2010‐2017) and the treatment outcome by analysing best response, progression‐free survival (PFS) and OS.…”

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma

“…However, low-risk patients (stage I–II) could receive four cycles of R-CHOP + two additional doses of rituximab. 19 , 37 As a whole, R-CHOP cures 70% of patients, 2 , 38 – 40 but patients with localized disease have an OS of up to 92%. 19…”

Therapy with of RCHOP-14 Versus RCHOP-21 for People With Aggressive or Advanced Stage Indolent B-Cell Non-Hodgkins Lymphoma: A Systematic Review and Meta-Analysis

“…Wästerlid 2017 [20] Knauf 2019 [19] Selection Representativeness of the exposed cohort * * Selection of the non exposed cohort * *…”